Dermata Therapeutics, Inc.

NasdaqCM:DRMA Stock Report

Market Cap: US$1.6m

Dermata Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of DRMA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies2,2200.147%
Institutions7,2590.481%
Individual Insiders14,5200.961%
General Public1,486,20098.4%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 610.3%.


Top Shareholders

Top 14 shareholders own 1.59% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
0.87%
Gerald Proehl
13,210US$14.3k0%no data
0.19%
Tower Research Capital Europe Limited
2,892US$3.1k66.8%no data
0.15%
Hale BioPharma Ventures LLC
2,220US$2.4k0%no data
0.14%
Wells Fargo & Company, Securities and Brokerage Investments
2,045US$2.2k4,440%no data
0.099%
UBS Asset Management AG
1,497US$1.6k-12.2%no data
0.054%
Geode Capital Management, LLC
815US$880.30%no data
0.034%
David Hale
515US$556.20%no data
0.017%
Wendell Wierenga
260US$280.90%no data
0.0081%
Kathleen Scott
123US$132.80%no data
0.0076%
Christopher Nardo
115US$124.10%no data
0.0067%
Andrew Sandler
101US$109.10%no data
0.0065%
Mary Fisher
98US$105.90%no data
0.0065%
Brittany Bradrick
98US$105.90%no data
0.00066%
Bank of America Corporation, Asset Management Arm
10US$10.8233%no data